Clinical

Dataset Information

0

Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET


ABSTRACT: Primary objectives: The main objective of the first part of the study is the demonstration of 89Zr-cetuximab uptake in non-hepatic tumour lesions. The main objective of the second part is the association between 89Zr-cetuximab uptake in non-hepatic tumour lesions and treatment outcome. Primary endpoints: Part one - Primary endpointThe detection of 89Zr-cetuximab uptake in non-hepatic tumour lesions (present/absent; present being defined as levels measured in ROI’s > standard deviation of background +1). Part two – primary endpointThe % uptake (of total injected) 89Zr-cetuximab in non-hepatic tumour lesions as measured in ROI’s corrected for background levels. Part two - secondary endpoints1) The % uptake (of total injected) 89Zr-cetuximab in liver lesions as measured in ROI’s corrected for background levels.2) [18F-]FDG PET measurements (SUVmax) before and after 4 weeks of treatment with cetuximab.3) Grade of skin toxicity as measured by predefined criteria (see below). Other study parameters4) Serum magnesium levels before and during treatment. 5) EGFR saturation with cetuximab in skin samples.6) Kinase activity in skin samples before and after treatment

DISEASE(S): Metastatic Colorectal Cancer,Advanced Colorectal Cancer

PROVIDER: 2528499 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 17685 | ecrin-mdr-crc
| 18849 | ecrin-mdr-crc
| 2164992 | ecrin-mdr-crc
2024-07-02 | GSE262796 | GEO
2023-07-18 | GSE205833 | GEO
2013-08-15 | E-GEOD-49012 | biostudies-arrayexpress
| 2462949 | ecrin-mdr-crc
2021-09-10 | GSE183790 | GEO
2021-06-01 | GSE169712 | GEO
2019-09-21 | E-MTAB-8340 | biostudies-arrayexpress